Long-Acting Insulin
Insulin Glargine
Insulin glargine is a long-acting insulin injected once a day for adults and children with diabetes. It is sold as Lantus, Basaglar, Toujeo (300 units per mL) and the biosimilars Semglee, Rezvoglar and Langlara, plus unbranded versions; all three biosimilars, and unbranded insulin glargine-yfgn, are licensed as interchangeable with Lantus. Low blood sugar is the main risk.
This page is general information about a medication and how cash prices for it are set. It is not medical advice and does not replace the label, your prescriber or your pharmacist. How we handle medical information
No generic exists, but Semglee, unbranded insulin glargine-yfgn, Rezvoglar and Langlara are interchangeable biosimilars for Lantus. No biosimilar to Toujeo is approved; the FDA Purple Book lists each product’s status.
About Insulin Glargine
Insulin glargine is a long-acting human insulin analog used as background insulin; in type 1 diabetes it is paired with a short- or rapid-acting mealtime insulin. The labels approve it to improve blood sugar control in adults and children with diabetes: the pediatric studies enrolled children 6 to 15 with type 1 diabetes, Toujeo is labeled from age 6, and Basaglar covers children with type 1 diabetes only. It is not recommended for diabetic ketoacidosis. It is injected once a day at the same time. With Lantus, people with type 2 diabetes not yet on insulin start at 0.2 units per kg or up to 10 units once a day, and people with type 1 at about a third of their total daily insulin.
There is no boxed warning. It must not be used during an episode of low blood sugar or by anyone allergic to insulin glargine or an ingredient. Low blood sugar is the most common adverse reaction and can be severe, and any change of insulin product or injection method is made under close medical supervision. Mix-ups between insulin products have happened, so the label is checked before every injection, and pens, needles and syringes are never shared. Severe allergic reactions and low potassium can occur, and with pioglitazone or a similar drug it can cause fluid retention and heart failure. Unit for unit, Toujeo lowers blood sugar less than Lantus, so people switching from Lantus usually need a higher Toujeo dose, and switching from Toujeo to a 100 units per mL glargine starts at a lower dose.
Semglee (insulin glargine-yfgn) was approved in July 2021 as the first interchangeable biosimilar insulin and is also sold unbranded as insulin glargine-yfgn; Rezvoglar (insulin glargine-aglr) was licensed as interchangeable in November 2022. Langlara (insulin glargine-aldy), a pen approved in April 2026, was licensed as biosimilar to and interchangeable with the Lantus SoloStar pen. Basaglar, approved in 2015 under a drug application and licensed as a biologic since March 2020, is neither a biosimilar nor interchangeable with Lantus. Toujeo is also sold unbranded as Insulin Glargine U-300. Needles are not included with the pens, so pen needles are a separate item.
Taking Insulin Glargine
- How to take it
- Under the skin of the abdomen, thigh or upper arm once a day at the same time, rotating the spot within the same area to lower the risk of thickened skin or lumps. Never dilute it, mix it with another insulin, use it in a pump or inject it into a vein, and never draw Toujeo from its pen into a syringe.
- If you miss a dose
- Ask the prescriber ahead of time what to do if you forget a dose or accidentally take an extra one, and write the directions down.
- Storage
- Unopened in the refrigerator, never frozen. Once opened, 100 units per mL vials last 28 days in the refrigerator or at room temperature up to 86°F, and pens 28 days at room temperature only; Toujeo pens last 56 days at room temperature only.
- Interactions to know about
- Other diabetes medicines, ACE inhibitors, ARBs, fluoxetine and fibrates can raise the risk of low blood sugar; steroids, diuretics, estrogens and antipsychotics such as olanzapine can raise blood sugar; alcohol, beta blockers, clonidine and lithium can do either, and beta blockers and clonidine can hide a low.
This summarizes the official prescribing information. Your prescriber’s and pharmacist’s instructions, and the leaflet that comes with your medicine, take priority.
Why the cash price for Insulin Glargine differs from pharmacy to pharmacy
Each glargine product is priced by its own maker, and a quote is for the exact product, form and quantity dispensed. A prescription for Lantus, or for insulin glargine with substitution allowed, can be filled with an interchangeable biosimilar of the same form (vial or pen) where state law allows; Basaglar and Toujeo are not interchangeable with Lantus, so neither is swapped for it at the counter.
Vials and pens are separate products with separate quotes, and the box size, the daily dose and the in-use limit decide how long a fill lasts. Pen needles and syringes are quoted separately, and each pharmacy adds its own dispensing fee and markup.
Upload it and licensed pharmacies reply with their own cash price. You pay the pharmacy, not us.
Ways to pay less for Insulin Glargine without insurance
- Ask the prescriber to write for insulin glargine, or for Lantus with substitution allowed, so the pharmacy can quote an interchangeable biosimilar.
- If you can draw doses with a syringe, ask the prescriber whether vials would suit you, and ask for quotes on both.
- Manufacturers run patient programs whose terms change; ask the maker of your product whether one applies to someone paying cash.
- Ask for a quantity that matches your dose and the in-use limit, and never stretch or skip doses to make insulin last.
- Upload the prescription to Script Unlock so licensed pharmacies can quote their cash price. You pay the pharmacy directly.
How Script Unlock gets you a cash price for Insulin Glargine
Prices on this site come from pharmacies responding to a real prescription. We do not publish estimated, average or "typical" prices, because none of those would be your price.
- 1You upload your prescription
A photo of your Insulin Glargine prescription is enough. Nothing is sold on the site; you are asking pharmacies to quote.
- 2Licensed pharmacies respond
Pharmacies that Script Unlock has verified see the request and each can reply with its own cash price for your exact drug, strength and quantity.
- 3You choose and pay the pharmacy
You compare the responses, pick a pharmacy, and pay that pharmacy directly when you collect. Script Unlock never takes a patient payment and never sets the price.
Questions to ask your pharmacist about Insulin Glargine
- 1.Which glargine product is this, and was it substituted for the one my prescriber named?
- 2.How long can I use this pen or vial once it is opened?
- 3.Which pen needles fit this pen, and do they need their own prescription here?
- 4.If I switch between Toujeo and a 100 units per mL glargine, how will my dose change?
Where Insulin Glargine fits
Vets prescribe it too. See Insulin for diabetic pets for pets for the safety points that differ in animals.
Related medications
Sources
- FDA-approved labeling on DailyMed (insulin glargine)
- MedlinePlus drug information (National Library of Medicine)
- FDA Purple Book (biologics, biosimilars and interchangeable products)
- FDA, biosimilar product information (content current as of October 2026)
- FDA approval letter, Semglee vial and pen determined interchangeable (BLA 761201, July 2021)
- FDA approval letter, Rezvoglar licensed as interchangeable with Lantus (BLA 761215, November 2022)
- FDA approval letter, Langlara licensed as biosimilar to and interchangeable with the Lantus SoloStar pen (BLA 761412, April 2026)
- Drugs@FDA, Semglee (BLA 761201): vial and pen marketed
- Drugs@FDA, Langlara (BLA 761412): approved 29 April 2026
- Drugs@FDA, Basaglar (BLA 205692): approved December 2015, former NDA deemed a BLA in March 2020
- DailyMed, Lantus prescribing information (revised May 2025)
- DailyMed, Toujeo prescribing information (revised May 2025)
- DailyMed, Insulin Glargine U-300 (the label states this product is Toujeo)
- DailyMed, Semglee prescribing information (revised March 2025)
- DailyMed, insulin glargine-yfgn (the label states this product is Semglee)
- DailyMed, Rezvoglar KwikPen prescribing information (revised August 2024)
- DailyMed, Langlara prescribing information (revised July 2026)
- DailyMed, Basaglar KwikPen and Tempo Pen prescribing information
- MedlinePlus, insulin glargine
Script Unlock is a marketplace that lets licensed pharmacies quote a cash price on your prescription. It does not prescribe, dispense or sell medication, does not process patient payments, and does not give medical advice. Always follow the instructions of your prescriber and pharmacist and read the medication guide supplied with your medicine.